MedPath

Rocuronium

Generic Name
Rocuronium
Drug Type
Small Molecule
Chemical Formula
C32H53N2O4
CAS Number
143558-00-3
Unique Ingredient Identifier
WRE554RFEZ

Overview

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Background

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Indication

For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Conditions

  • Muscle fasciculation caused by succinylcholine

FDA Approved Products

Rocuronium Bromide
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:100 mg in 10 mL
Approved: 2019/03/31
NDC:43066-013
Rocuronium Bromide
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2024/03/05
NDC:0143-9250
Rocuronium Bromide
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2024/03/05
NDC:0143-9251
Rocuronium Bromide
Manufacturer:Meitheal Pharmaceuticals Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2023/05/09
NDC:71288-700
ROCURONIUM BROMIDE
Manufacturer:HF Acquisition Co LLC, DBA HealthFirst
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2024/01/28
NDC:51662-1354

Singapore Approved Products

ESMERON INJECTION 50 mg/5ml
Manufacturer:N V ORGANON, Siegfried Hameln GmbH
Form:INJECTION
Strength:10 mg/ml
Online:Yes
Approved: 1997/08/19
Approval:SIN09479P
NOVERON SOLUTION FOR INJECTION 10MG/ML
Manufacturer:PT. Novell Pharmaceutical Laboratories
Form:INJECTION, SOLUTION
Strength:10mg/ml
Online:Yes
Approved: 2024/06/12
Approval:SIN17025P
ROCURONIUM KABI SOLUTION FOR INJECTION/INFUSION 10MG/ML
Manufacturer:Fresenius Kabi Austria GmbH
Form:INJECTION, SOLUTION
Strength:10mg/ml
Online:Yes
Approved: 2016/10/25
Approval:SIN15106P
ROCURONIUM-HAMELN INJECTION 10MG/ML
Manufacturer:Siegfried Hameln GmbH
Form:INJECTION, SOLUTION
Strength:10 mg/1ml
Online:Yes
Approved: 2017/05/16
Approval:SIN15237P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath